Lab
Ylab180 INC
Ylab180 INC was paid $4.62M by Medicaid between Aug 2022 and Jun 2024, across 9 billing codes. Its largest line is 87637, Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV — 41% of everything it billed.
33Billing provider infoYLAB180 INC
ADDISON, IL 60101
ADDISON, IL 60101
33aNPI1184385379assigned 01/10/2022
33bProvider typeClinical Medical Laboratory
28Total paid$4.62M
24GClaims78,613
24DCodes billed9
24AFirst – last monthAug 2022 – Jun 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Illinois
Rank by total paid#40 of 235
Median peer was paid$123K
This provider vs. median38×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 3,647 | $161K | |
| 2023 | 67,621 | $3.71M | |
| 2024incomplete | 7,345 | $749K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 41% | 16,907 | 8,611 | $1.90M |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 19% | 22,256 | 13,988 | $871K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 17% | 10,703 | 7,005 | $788K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 9.8% | 14,385 | 8,492 | $454K |
| 0240U | 4.6% | 1,846 | 1,670 | $212K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 4.4% | 8,341 | 6,992 | $204K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.8% | 3,894 | 2,657 | $178K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 220 | 162 | $3K |
| 87420 | <1% | 61 | 54 | $763.79 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKHAN, MIR (MANAGING DIRECTOR)